Friday 23 May 2025
  • About
  • Contact
  • Login
  • VC & Investment
  • M&A
  • AI
  • Podcasts
  • News
    • Pharmaceutical News
    • Biotechnology News
    • Generics News
    • Biosimilars news
    • In Brief
    • Legal
    • Company Pages
    • In The Boardroom
  • Insights
    • Analysis
    • Special Report
    • Interviews
    • Expert View
    • From Our Correspondent
    • One To Watch Companies
    • Digital Pharma
    • Pharma Leaders
  • Regulatory
    • FDA
    • EMA
    • Pricing, Reimbursement and Access
    • Regulation
    • Government Affairs
    • Trump Administration
  • Therapy Areas
    • Dermatologicals
    • Oncology
    • Neurological
    • Rare Diseases
    • Hematology
    • Cardio Vascular
    • Diabetes
    • Cell And Gene Therapy
  • Conferences
    • JPM Healthcare Conference
    • ESMO
    • ASCO
    • ASH
    • EULAR
    • AAIC
    • EASD
    • Forthcoming Events
  • Ones to Watch
  • About
  • Contact
  • Newsletter
  • Sign inSubscribe
Subscribe
  • Home
  • Pharmexa and Affitech link as new Ab firm

Pharmexa and Affitech link as new Ab firm

16 March 2009

Denmark's Pharmexa A/S and privately-held Norwegian firm Affitech AS have entered into a conditional agreement to merge the two companies by  means of a share for share transaction. The purpose is to transform  Pharmexa from a cancer and infectious disease vaccine business into a  company focused on the R&D of human antibody therapeutic drugs.

Under the terms of the accord, Pharmexa will offer to acquire 100% of  the outstanding and issued share capital of Affitech in exchange for  newly-issued stock of Pharmexa. On completion of the transaction,  Affitech's shareholders will own about 70% and Pharmexa's 30% of the  merged group. The combined company will be renamed Affitech A/S and it  is aimed to continue its listing on the Nasdaq OMX exchange in  Copenhagen. The existing Affitech drug discovery business in Oslo will  be renamed Affitech Research AS. As part of the merger, certain Affitech  shareholders will undertake to participate in a new share issue which  Pharmexa expects to take place during the second or third quarter of  this year.

Announcing the merger, Achim Kaufhold, chief executive of the Danish  firm, said: "Pharmexa has experienced product setbacks over the last  year which have led us to consider a variety of strategic options to  revitalize the business and to generate future value for our  shareholders. The acquisition of Affitech builds on the expertise and  capabilities of Pharmexa, but is also a transformational event that  moves us into the exciting field of antibody therapeutics, one of the  most attractive sectors of the biopharmaceutical industry. Following  several high-value mergers and acquisitions in the antibody discovery  field, Affitech remains one of only a limited number of independent  companies with a strong position in high-throughput screening of  antibody libraries."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Try before you buy

 

Free

7 day trial access

Take a Free Trial
  • All the news that moves the needle in pharma and biotech
  • Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
  • Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news

Today's issue

CureDuchenne to bring in Brenda Wong
Pharmaceutical
CureDuchenne to bring in Brenda Wong
22 May 2025
Biosimilars
Samsung Biologics to spin off biosimilar unit, launching a two-track strategy
22 May 2025
Pharmaceutical
FDA takes steps to enhance state medicines importation
22 May 2025
Biotechnology
Fore Biotherapeutics raises $38 million
22 May 2025
Biotechnology
Jiangsu Hengrui offers indication of Chinese fundraising strength
22 May 2025
Biotechnology
Sanofi to expand CNS pipeline with buy of Vigil Neuroscience
22 May 2025
Pharmaceutical
UroGen tanks as FDA panel vote goes against UGN-102
22 May 2025

Company Spotlight

A Munich, Germany-based biotech company in the antibody drug conjugate (ADC) space.






The Pharma Letter

39-43 Putney High Street, Putney
London, SW15 1SP
United Kingdom

  • About us
  • Contact
  • Subscribe
  • Sponsorship/advertising


  • Terms and Conditions
  • Privacy Policy
  • Twitter
  • Linkedin

Copyright © The Pharma Letter 2025   |   Headless Content Management with Blaze